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Abstract
Background: It has been suggested that cigarette smokers will switch to alternative oral nicotine delivery products
to reduce their health risks if informed of the relative risk difference. However, it is important to assess how
smokers are likely to use cigarette alternatives before making predictions about their potential to promote
individual or population harm reduction.
Objectives: This study examines smokers’ interest in using a smokeless tobacco or a nicotine replacement product
as a substitute for their cigarettes.
Methods: The study included 67 adult cigarette smokers, not currently interested in quitting, who were given an
opportunity to sample four alternative oral nicotine products: 1) Camel Snus, 2) Marlboro Snus, 3) Stonewall
dissolvable tobacco tablets, and 4) Commit nicotine lozenges. At visit 1, subjects were presented information about
the relative benefits/risks of oral nicotine delivery compared to cigarettes. At visit 2, subjects were given a supply
of each of the four products to sample at home for a week. At visit 3, subjects received a one-week supply of their
preferred product to see if using such products reduced or eliminated cigarette use.
Results: After multiple product sampling, participants preferred the Commit lozenges over the three smokeless
tobacco products (p = 0.011). Following the one week single-product trial experience, GEE models controlling for
gender, age, level of education, baseline cigarettes use, and alternative product chosen, indicated a significant
decline in cigarettes smoked per day across one week of single-product sampling (p < 0.01, from 11.8 to 8.7
cigarettes per day), but no change in alternative product use (approximately 4.5 units per day). Biomarkers of
exposure showed no change in cotinine, but a 19% reduction in exhaled CO (p < 0.001).
Conclusions: Findings from this study show that smokers, who are currently unwilling to make a quit attempt,
may be willing to use alternative products in the short term as a temporary substitute for smoking. However, this
use is more likely to be for partial substitution (i.e. they will continue to smoke, albeit at a lower rate) rather than
complete substitution. Of the various substitutes offered, smokers were more willing to use a nicotine replacement
product over a tobacco-based product.
Background
While the harms of tobacco smoking have been well
documented for decades, more than 20% of US adults
continue to smoke[1]. This seeming lack of progress has
led to interest in harm reduction as a complementary
tobacco control strategy, particularly with products that
offer reduced toxicity to individual users[2]. Two
products that have received substantial discussion as
potential harm reduction options are smokeless tobacco
(particularly low-toxin forms such as Swedish snus) and
nicotine replacement therapy (medicinal nicotine),
which is currently approved only for limited duration
use in smoking cessation[3-7]. However, the promotion
of reduced harm products, especially smokeless tobacco,
remains controversial. Commonly expressed concerns
include a lack of reliable data on health risk reduction
(as opposed to exposure), impacts on smoking behavior
(e.g., dual use and continued nicotine dependence), and
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non-users of tobacco, especially youth[2,8-11]. Further
complicating matters is the fact that since 2005, major
cigarette manufacturers have, either through partnership
or acquisition, moved into the smokeless tobacco busi-
ness. This has allowed tobacco manufacturers to intro-
duce smokers to new smokeless tobacco products for
use in situations where smoking is restricted[12-14].
Consumer perceptions and responses are key compo-
nents to understanding the adoption and maintenance
of new and modified tobacco products[15]. The Family
Smoking Prevention and Tobacco Control Act of 2009
(FSPTCA) empowers the FDA to regulate tobacco pro-
ducts by considering consumer perceptions in decisions
about regulations “appropriate for the protection of pub-
lic health”[16]. So, knowing what users believe about
products, and their reactions to those products, are
recognized to be important to understanding how smo-
keless tobacco and medicinal nicotine are likely to be
used and thus their potential as substitutes for cigar-
ettes. However, independent research has been limited
in this area. Timberlake [17] found only 13% of Califor-
nia smokers were receptive to using smokeless tobacco
instead of smoking. Studies outside North America have
found that 34% of New Zealand smokers and 48% of
Australian smokers were interested in trying smokeless
tobacco[18,19]. Interest in switching from cigarettes to
an alternative form of nicotine delivery may depend on
smokers’ preexisting beliefs about alternative products.
Data consistently show that consumers incorrectly
believe nicotine causes cancer,[20-22] and that smoke-
less tobacco products are as, if not more, dangerous
than cigarettes[23-26]. So, the information presented
about products may be an important factor in influen-
cing interest. Shiffman and colleagues [27] presented
smokers with descriptions of both medicinal nicotine
and tobacco-based products positioned as smoking sub-
stitutes, and found that smokers generally preferred the
medicinal nicotine products to the tobacco-based pro-
ducts. On the other hand, Heavner and colleagues[28]
surveyed smokers in Edmonton, Canada, and reported
that 75% were willing to try a hypothetical product car-
rying 99% less risk than smoking. However, neither of
these studies involved direct experience.
Recently, Carpenter and Gray [29] reported that, com-
pared to continued smoking, use of Ariva or Stonewall
compressed tobacco lozenges reduced cigarette con-
sumption and increased intentions to quit. A series of
studies by Schneider and colleagues [30-32] examined
preferences among different nicotine replacement pro-
ducts, concluding that individuals have varied reactions
to different nicotine delivery modes, and sampling of
treatments can identify key reactions that predict later
quitting success. Caldwell and colleagues [33] found
that, among heavy smokers given two-weeks experience,
snus or Zonnic oral nicotine sachet were preferred over
nicotine gum. Cobb and colleagues [34] using a series of
laboratory sessions with smokers, showed that non-com-
bustible products (Ariva, Camel Snus, Marlboro Snus,
Commit) delivered less nicotine than smokers usual
brand of cigarettes and failed to suppress tobacco absti-
nence symptoms as effectively as cigarettes. Overall, the
literature suggests that it is important to try to assess
smokers’ reactions to proposed cigarette alternatives
before making predictions about their potential to pro-
mote harm reduction relative to continued smoking.
The present study was designed to examine smokers’
interest in using a smokeless tobacco (SL) or nicotine
replacement product (NR) as a substitute for their cigar-
ettes. Specifically, we set out to address three questions:
1) Among various options, which alternative source of
oral nicotine delivery do smokers prefer? 2) When given
an opportunity to use their preferred product, how
would they use it (i.e., complete or partial substitution)?
3) Would brief ad libitum use of the oral nicotine sub-
stitute alter exposure to cigarettes as assessed by CPD,
carbon monoxide and nicotine levels?
Methods
Study Participants
Recruitment occurred via community flyers and adver-
tisements in local newspapers, which sought smokers
interested in trying alternative tobacco and nicotine pro-
ducts. Participants were eligible if they smoked ten or
more cigarettes per day for at least one year, were not
currently using any other nicotine or tobacco product,
were able to read and write in English, had no medical
contraindications (e.g., heart disease) for nicotine repla-
cement use, had not made a quit attempt in the pre-
vious 30 days, and were not planning to quit in the next
30 days. Sixty-seven participants met eligibility criteria,
of whom 44 completed the entire study. Demographics
for those who did or did not complete the study are
show in Table 1. Overall, only prior use of NRT signifi-
cantly differentiated the completers from those lost to
follow-up.
Study design
Participants visited the laboratory for four separate ses-
sions (each one week apart) between June and Decem-
ber 2008, as part of a broader study of the effects of
information on knowledge of tobacco and nicotine
harms (Borland et al., in preparation). Figure 1 outlines
the study course for participants. Sessions 1 and 2 pre-
sented information about the relative risks of smokeless
tobacco and nicotine replacement products compared to
cigarettes to provide a health-based rationale for consid-
ering these products as alternatives. The findings related
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Session 2, after completing a questionnaire, participants
were offered the opportunity to sample four different SL
and NR products (Multiple-Product Sampling). Partici-
pants were given one package of each of four SL/NR
products (detailed below), with instructions to use each
product at least once and then to use as much of these
products as they wished over the following week. Base-
line carbon monoxide (CO) and saliva samples (e.g, sali-
vary cotinine) were obtained at this time. One week
later, participants returned for Session 3, completed a
questionnaire about their experiences with the four trial
products and were given the opportunity to select their
preferred SL/NR product out of the four trial products
and use it for one more week (Single-Product Trial).
Participants were provided with this additional week-
l o n gs u p p l yo ft h e i rc h o s e np r o d u c ta tn oc o s ta n d
asked to record their usage patterns in a daily diary.
They were asked to bring all of their tins and any
unused portions to their next lab visit to confirm self-
reported usage. One week later, participants completed
Session 4, consisting of a follow-up questionnaire and
collection of CO and saliva samples. Participants
received $10 per visit for completion of the first 3 visits
and $25 for completion of the fourth visit for a maxi-
mum possible compensation of $55. The study protocol
was approved by the Roswell Park Cancer Institute
Institutional Review Board, and all participants provided
documented informed consent prior to participation.
Products
All test products were purchased on the open market in
2008 and previous studies have examined characteristics
of these or similar products[35-37]. At the end of Ses-
sion 2, participants were provided with samples of three
smokeless tobacco products [one container each of
Camel Snus, 20 pouches; Marlboro Snus, 12 pouches;
and Stonewall Hard Snuff, 20 tablets] and one package
of oral nicotine replacement product (Commit
®
Lozenge, 24 4 mg lozenges). The smokeless products
contained varying amounts of free nicotine - from 0.7
mg/g (Marlboro Snus Mint) to 1.5 mg/g (Stonewall) to
6.4 mg/g (Camel Snus Frost)[36,37]. For standardization
purposes, all products were offered only in their ‘mint’
Table 1 Demographic characteristics of study participants (N = 67)
Variable Levels Lost to follow-up Completed Study p-value*
(n = 23) (n = 44)
Gender Female 52.247.8 52.3 0.994
Male 47.7
Highest Level of Education Less than HS 39.1 20.5 0.053
HS Graduate 34.8 22.7
More than HS 26.1 56.8
Age < 40 30.4 18.2 0.379
41 - 54 60.9 63.6
55 + 8.7 18.2
Race White 56.5 67.4 0.183
Black 43.5 25.6
Other 0 7
Intention to Quit in the next year No 8.7 15.9 0.411
Yes 91.3 84.1
How addicted do you consider yourself? Very 78.3 72.7 0.274
Somewhat 17.4 27.3
Not at all 4.3 0
Prior use of NR Yes 26.1 52.3 0.04
No 73.9 47.7
Prior use of ST Yes 8.7 11.488.6 0.735
No 91.3
Cigarettes per Day Mean 21.4 22.2 0.519
(SE) -3.7 -1.9
Minutes to First Cigarette after Waking Median 5 5 0.662
(IQR) (2-15) (5-15)
* categorical variables compared by chi-square; continuous variables compared by Wilcoxon test, p-value < 0.05.
HS = High school.
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not drive selections. At the end of Session 3, partici-
pants selected one of these four products to use for an
additional week and received 7 containers/packages of
that product.
Measures
Questionnaire items focused on the specific SL/NR
products offered and their experiences with the pro-
ducts, including which product overall they liked
most/least, willingness to use the products instead of
smoking under a range of scenarios, and interest in
actually continuing to use such products as a partial or
complete replacement for cigarettes. Participants were
also asked a series of questions pertaining to their will-
ingness to pay for the smokeless and nicotine replace-
ment products. Daily diaries were used to track
numbers of cigarettes and substitute products used
each day. At baseline participants self-reported their
usual number of cigarettes per day and time to first
cigarette after waking, which were recoded into the
Heavy Smoking Index (HSI) [38]. Exhaled CO was
tested using a Micro 4 Smokerlyzer (Bedfont, UK)
using standard protocols. Cotinine in saliva was tested
using the EIA method by an outside laboratory (Sali-
metrics LLC, University Park, PA).
Data analysis
All analyses were performed using SPSS 16.0 (Chicago,
IL). Descriptive statistics and frequencies were used to
initially characterize the data. Kendall’st a u - bw a su s e d
to examine concordance between product rankings.
Change in responses over time was examined using
paired t-tests. Cotinine values were transformed using
the natural logarithm to normalize the distribution prior
to analysis. Generalized estimating equations (GEE) with
log link and first-order autoregressive working correla-
tion matrix were applied to examine daily patterns of
product use; a normal distribution best fit models of
cigarette use, while a gamma distribution best fit models
of alternative product use. Statistical significance was
accepted at a p-value of <0.05.
Figure 1 Flowchart detailing study involvement of participants.
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Multiple-product sampling
Of the initial 67 participants, 59 remained in the study
to sample products. However, seven were lost to follow-
up and two were excluded because they did not use the
provided products. Table 2 presents information on use
of each product and opinions related to each product as
assessed at Session 3. Participants did not use a large
amount (between 10% and 20%) of each product sup-
plied, and they appear to have distributed their product
usage approximately equally across all products. How-
ever, their post-sampling choices were non-random,
with Commit lozenge the most well-liked and Stonewall
the least liked products (Kendall’s tau-b = -0.314, p =
0.011). Further, participants believed Camel Snus to
contain the most nicotine, while Commit was consid-
ered to have the least. No relationship was observed
between perceived nicotine content and positive product
rating (Kendall’s tau-b = -0.119, p = 0.338) or negative
product rating (Kendall’s tau-b = 0.024, p = 0.832).
There were no significant associations between the pre-
ferred product and participant gender, age, intention to
quit smoking, HSI score, or ever use of ST or NR
products.
Patterns of use
As illustrated in Figure 2, over the course of the seven-
day sampling phase, both cigarette use (12.0 cigarettes
on day 1 to 10.8 cigarettes on day 7; p = 0.509) and
alternative product use (3.2 units on day 1 to 3.3 units
on day 7; p = 0.512) were fairly consistent. This was
confirmed in GEE models controlling for gender, age
(categorized as <40, 41-54, ≥55 years), level of educa-
tion, Heavy Smoking Index score, and alternative pro-
duct most preferred, where we observed no significant
effect of day for cigarettes and alternative products (see
Table 3). HSI score was positively associated with cigar-
ette use over the sampling week, but not with alternative
product use.
Single-product trial
Of the 50 participants who sampled multiple products,
49 selected a preferred product to use for one additional
week, while one declined to use any products. Of these,
five did not complete the final visit. As expected, choice
of product following the one week trial period closely
mirrored reports of which product participants liked
most after multiple-product sampling (Kendall’s tau-b =
0.907, p < 0.001), with 14% choosing Camel Snus, 29%
choosing Marlboro Snus, 12% choosing Stonewall, and
45% choosing Commit Lozenge. While no overall signif-
icant effects by product were observed, Table 4 suggests
participants who preferred Camel Snus anticipated using
it in addition to cigarettes, moreso than those preferring
other alternative products. However, they differed signif-
icantly in the median amount they were willing to pay
for a container/package of that product, from a low of
$2 for Stonewall to $5 for Commit Lozenge, with sub-
stantial inter-individual variability. 80% of participants
reported that they were very or somewhat likely to pur-
chase their preferred product in the next year.
Patterns of Use
As illustrated in Figure 3, over the course of the seven-
day trial phase, daily cigarette use decreased from 11.8
to 8.7 cigarettes on average (a 25% reduction; p =
0.004), while alternative product was relatively stable
( 4 . 7u n i t sa td a y1t o4 . 7u n i t sa td a y7 ;p=0 . 7 7 7 ) .N o
participant stopped using cigarettes completely. Table 3
shows results of GEE models controlling for gender,
age, level of education, HSI score, and alternative pro-
duct chosen. We observed a significant effect of day [p
Table 2 Alternative product preferences (N = 50)
Camel Snus Marlboro Snus Stonewall Commit 4 mg
Proportion of supplied units used (Median, IQR) 10 16.7 10 12.5 c
2(3) = 589.31
(5-25) (8-58) (5-28) (4-33) p = 0.003
a
Proportion of all products used (Median, IQR) 20 23.4 22.2 25 c
2(3) = 142.2
(9-25) (9-35) (8-33) (15-50) p = 0.524
a
c
2(3) = 005.31
Product Liked Most (%) 12.5 31.2 12.5 43.8 p = 0.004
b
c
2(3) = 333.8
Product Liked Least (%) 27.1 10.4 39.6 22.9 p = 0.040
b
c
2(3) = 519.8
Product believed to contain most nicotine (%) 42.6 21.3 23.4 12.8 p = 0.030
b
c
2(3) = 944.31
Product selected for one-week trial (%)
c 14.3 28.6 12.2 44.9 p = 0.004
b
IQR = interquartile range.
a. Friedman test; b. One-sample chi-square test.
c. One participant declined to use any product for the one-week trial.
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smoked per day across the week. Cigarette use across
the week was also related to education, with smokers
having less than HS education smoking significantly
more cigarettes than those with more than HS educa-
tion. Age was also associated with cigarette use, with
those aged 40 or less smoking fewer cigarettes than
those aged 55 or higher. Alternative product preferred
was not associated with cigarette use during the trial
week. In contrast, GEE models showed no significant
change in alternative product use across the week, indi-
cating stability in use. However, HSI was positively asso-
ciated with alternative product use during the trial
week–those with higher scores used more units of their
chosen product. We also noted an overall effect of edu-
cation [Wald c
2(2) = 13.828, p = 0.001], wherein those
had less than HS education used fewer alternative pro-
ducts than those with more than HS education. No sta-
tistically significant relationships between alternative
product use and gender, age, or preferred product were
noted; model adjusted mean use for those who preferred
Camel Snus was 3.0 units/day over the week, compared
to 3.9 units/day for Marlboro Snus, 4.5 units/day for
Commit, and 2.7 units/day for Stonewall.
Biomarkers of exposure
Exhaled CO decreased significantly from before to after
the one-week trial. Exhaled CO before any use of alter-
native products (Session 2) averaged 18.7 ppm (SD 7.0),
and dropped after the one week trial (Session 4) to an
average of 14.9 ppm (SD 7.2), a decline of 10% [t(43) =
4.149; p < 0.001]. Overall, 75% of participants demon-
strated a decrease in breath CO levels. Geometric mean
salivary cotinine was observed to remain stable; at Ses-
sion 2 saliva cotinine was 311.0 ng/mL, compared to
311.9 ng/mL at Session 4 [t(41) = -0.043; p = 0.966].
We calculated a compensation index for cotinine rela-
tive to CO using the formula COMP = 1 - (ln (COT4) -
ln(COT2))/(ln(CO4) - ln(CO2)). The median compensa-
tion score was 1.02 (IQR 0.38-1.60), suggesting that on
average, smokers in the study compensated completely
for their nicotine needs by substituting alternative
Figure 2 Alternative product versus cigarette patterns of use during multiple-product sampling (N = 50) phase.
O’Connor et al. Harm Reduction Journal 2011, 8:1
http://www.harmreductionjournal.com/content/8/1/1
Page 6 of 10Table 3 Parameter Estimates from GEE modeling of cigarette and alternative product use during multiple product
sampling and single-product trial phases
Cigarettes Alternative Products
B SE Wald c
2 (df = 1) p B SE Wald c
2 (df = 1) p
MULTIPLE PRODUCT SAMPLING PHASE
Intercept 1.966 0.354 30.911 <.001 0.682 0.486 1.969 0.161
Day -0.012 0.019 0.436 0.509 -0.015 0.022 0.43 0.512
Female (ref = Male) 0.046 0.104 0.193 0.66 -0.029 0.185 0.024 0.877
Less than HS (ref = More than HS) 0.044 0.117 0.143 0.705 -0.454 0.177 6.611 0.01
HS graduate (ref = More than HS) -0.08 0.149 0.287 0.592 -0.204 0.188 1.173 0.279
40 and under (ref = 55 and older) -0.186 0.186 1.003 0.317 0.036 0.193 0.034 0.854
41-54 (ref = 55 and older) -0.169 0.14 1.457 0.227 0.139 0.203 0.468 0.494
Camel Snus (ref = Stonewall) -0.135 0.187 0.524 0.469 0.489 0.228 4.608 0.032
Marlboro Snus (ref = Stonewall) -0.154 0.145 1.131 0.288 0.418 0.234 3.19 0.074
Commit (ref = Stonewall) -0.274 0.158 3.006 0.083 0.515 0.216 5.685 0.017
HSI 0.211 0.049 18.591 <.001 0.022 0.071 0.092 0.762
SINGLE PRODUCT TRIAL PHASE
Intercept 1.762 0.471 13.987 <.001 0.414 0.526 0.62 0.431
Day -0.039 0.014 8.186 0.004 -0.006 0.023 0.08 0.777
Female (ref = Male) -0.128 0.145 0.787 0.375 -0.084 0.177 0.227 0.634
Less than HS (ref = More than HS) 0.344 0.139 6.307 0.012 -0.568 0.181 9.855 0.002
HS graduate (ref = More than HS) -0.071 0.131 0.295 0.587 -0.026 0.206 0.016 0.898
40 and under (ref = 55 and older) -0.443 0.192 5.31 0.021 -0.283 0.266 1.134 0.287
41-54 (ref = 55 and older) -0.264 0.154 3.299 0.069 0.044 0.216 0.041 0.839
Camel Snus (ref = Stonewall) 0.16 0.203 0.617 0.432 0.091 0.283 0.102 0.749
Marlboro Snus (ref = Stonewall) -0.18 0.171 1.109 0.292 0.358 0.312 1.312 0.252
Commit (ref = Stonewall) 0.007 0.19 0.001 0.97 0.49 0.263 3.467 0.063
HSI 0.245 0.061 16.386 <.001 0.234 0.081 8.265 0.004
NOTE: HSI = Heavy Smoking Index.
Parameter estimates in bold indicate statistically significant effects.
Table 4 Participant likelihood to use, purchase, & pay for alternative products (N = 44)
Preferred product (Overall) Camel Snus Marlb Snus Stone-wall Commit 4 mg Test/p-value*
Likely to use instead of cigarettes (%)
Very 20.5 14.3 15.4 0 31.6 c
2(6) = 96.4
Somewhat 45.5 42.9 46.2 40 47.4 p = 0.584
Not at all 34.1 42.9 38.5 60 21.1
Likely to use in addition to cigarettes (%)
Very 47.7 71.4 23.1 40 57.9 c
2(6) = 52.6
Somewhat 38.6 28.6 53.8 40 31.6 p = 0.396
Not at all 13.6 0 23.1 20 10.5
Likely to purchase in next year (%)
Very 38.6 28.6 30.8 0 57.9 c
2(6) = 12.7
Somewhat 40.9 42.9 46.2 60 31.6 p = 0.302
Not at all 20.5 28.6 23.1 40 10.5
Price willing to pay for one package ($)
Median 5 3 3 2 5 c
2(3) = 11.81
(IQR) (3.00-5.75) (2.00-3.00) (2.50-5.00) (1.00-4.00) (5.00-11.00) p < 0.001
* Likelihood variables tested by Pearson chi-square; price tested by Kruskal-Wallis.
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ferred product [Kruskal-Wallis c
2(3) = 0.76, p = 0.860].
Discussion
Findings from this study show that smokers who are
currently unwilling to make a quit attempt may be open
to adopting alternative products in the short term as a
temporary substitute for smoking. The two-step trial
period allowed us to explore smokers’ willingness to try
unfamiliar oral nicotine and smokeless tobacco pro-
ducts, as well as their perceptions and acceptability of
these products as an alternative to cigarettes. Data sug-
gest that the dominant behavioral pattern was partial
substitution, with about twice as many cigarettes con-
sumed compared to oral nicotine products. Although,
we observed that cigarette use declined by nearly one-
half during the monitoring interval. We did not collect
data to inform whether low use of the alternatives was a
result of participants ‘rationing’ product, but given the
number of unused portions returned, this was likely not
a major problem. It is more likely that participants had
not settled on a habitual use pattern, and/or the pro-
ducts were not sufficiently attractive.
Concomitant measurement ofb i o m a r k e r so fe x p o s u r e
revealed a small but significant decrease in breath CO
associated with use of alternative products, without any
change in salivary cotinine levels. The modest reduction
in CO exposure, while statistically significant, is unlikely
by itself to qualify as a true reduction in harm. In con-
trast, the downward trajectory of cigarette use, paired
with consistent use of alternative products, suggests that
ad libitum use of SL/NR might, over a longer time frame,
lead to substantial harm reduction; however, this must be
evaluated in longer term studies. The finding of a stable
level of substitution over the week of use is consistent
w i t ht h ep o s s i b i l i t yt h a ts m o k e r s ,a tl e a s tt h o s ew i t hl o w
interest in quitting, may prefer a gradual shift strategy to
an immediate changeover model (as occurs with use of
NRT to quit). We cannot predict from the current data
whether this process would continue and result in com-
plete substitution, ongoing mixed use, a reversion to
cigarettes, or complete cessation of nicotine use.
Figure 3 Alternative product versus cigarette patterns of use during (single-product trial (N = 44) phase.
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found that among smokers willing to try an oral nico-
tine product more were interested in using a pharma-
ceutical nicotine product (Commit) compared to three
alternative smokeless tobacco products. This finding of
willingness to use a nicotine replacement product for
temporary substitution is consistent with prior literature
showing substantial use of NRT products for reasons
other than quitting (e.g., smoking reduction, temporary
abstinence) by smokers [39,40] The observed preference
for the nicotine lozenge counters an implicit assumption
[41,42] that smokers would more likely prefer smokeless
tobacco to nicotine products. At the same time, the
greater the range of products offered, the greater the
proportion of smokers who may find a product they see
a sav i a b l es u b s t i t u t ef o rc i g a r e t t e s .T h i si sc o n s i s t e n t
with the body of literature [29-34] suggesting that smo-
kers’ varied reactions to different products may be infor-
mative in themselves, meaning a ‘sampling’ approach
may allow smokers to find an appealing alternative pro-
duct to cigarettes.
Participants identified Camel Snus as containing the
most nicotine and, while it was not preferred by many
(14%), a substantial majority (70%) of these reported they
were at least somewhat likely to purchase the product in
the next year (see Table 4). This observation may be
related to the higher ‘free’ nicotine content in Camel
Snus relative to the other products offered. In particular,
other investigators have pointed out the discrepancy
between Marlboro Snus and Swedish forms in terms of
free nicotine [43]. This difference in nicotine may explain
the discrepancy in preference between Camel and Marl-
boro Snus, which might seem superficially equivalent.
Moist snuff manufactures have altered free nicotine levels
to affect nicotine delivery and appeal to different markets
[44,45]. However, for smokers naïve to oral tobacco pro-
ducts, the higher free nicotine content of Camel Snus
may initially have been experienced as aversive while the
low free nicotine content of Marlboro Snus may have
been insufficiently satisfying to sustain use.
The findings from this study are subject to a number of
limitations. About 1/3 of initial participants did not com-
plete all phases of this study, reflecting the challenges of
multi-visit studies. The limited number of participants
also precluded identifying specific demographic predictors
of willingness to substitute or patterns of substitution. We
chose not to include a comparison group who continued
to use only cigarettes, because our primary interest was
observing what smokers might do when presented the
opportunity to try a different form of nicotine delivery.
In summary, this study reveals that the nicotine
lozenge was viewed more favorably than smokeless
tobacco products, as a substitute for cigarettes, which
counters some claims that ST would be more acceptable
to smokers. However, we observed no true switching (i.
e., abandoning cigarettes), even though SL and NR pro-
ducts were provided without cost. It is clear that simply
informing smokers of the lower risk and providing pro-
ducts is not going to result in major immediate shifts to
smokeless alternatives. In the absence of some signifi-
cant incentive, it is unlikely that information campaigns
alone would lead to migration from use of cigarettes
toward less hazardous nicotine sources among United
States smokers. Further work is needed of the longer-
term effects on attempts at substitution to see if poten-
tially significant effects, in public health terms, can be
achieved, or whether encouraging smokeless nicotine
use is not a viable substitution strategy.
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